MSI-78 is a cationic peptide with broad-spectrum antimicrobial activity and is being developed as a topical agent. We compared the in vitro activity of MSI-78 with those of ofloxacin and other antibiotics against fresh clinical isolates. Based on MIC distribution statistics, strains for which the MSI-78 MIC was <64 g/ml were assumed to be susceptible for purposes of this report. Of 411 aerobic isolates tested, 91% were susceptible to MSI-78, compared to 91% for ofloxacin and 92% for ciprofloxacin. Only enterococci consistently required >64 g of MSI-78/ml for inhibition. MSI-78 demonstrated bactericidal activity equivalent to that of ofloxacin. Of 61 anaerobes, 97% were susceptible to MSI-78. Of 10 isolates of Candida albicans, 3 were inhibited by MSI-78 at 24 h. Further studies of this compound appear to be warranted.
Magainins are a class of naturally occurring cationic peptides found in animals and have broad-spectrum antimicrobial activity through their interactions with anionic phospholipids of microbial cells, which result in disruption of the cell membranes (2, 6) . MSI-78 is a 22-residue magainin analog that is being developed for use as a topical antimicrobial agent (1, 2, 6) . In vivo studies have demonstrated a 5-log reduction in numbers of Pseudomonas aeruginosa organisms in swine skin wounds (5) and a 4-log reduction of perineal skin flora on human skin (3) following topical application of MSI-78. Two phase III clinical trials of MSI-78 have been completed for the treatment of infected diabetic foot ulcers. These trials were equivalency trials with orally administered ofloxacin as the comparator drug. MSI-78 applied topically was found to be statistically equivalent to orally administered ofloxacin with respect to clinical resolution of infection (3a) .
The present study was designed to compare the in vitro antimicrobial activity of MSI-78 with those of ofloxacin and other antimicrobial agents against a wide variety of aerobic and anaerobic bacteria and yeasts.
MATERIALS AND METHODS
Preliminary study. Because of the cationic nature of MSI-78, a variety of different media and incubation atmospheres were employed to test the susceptibility of 10 strains of Staphylococcus aureus to MSI-78 (see Table 1 ). Test procedures otherwise followed those outlined by the National Committee for Clinical Laboratory Standards (NCCLS) for broth microdilution and agar dilution (7).
Microorganisms. Fresh clinical isolates were obtained from local clinical microbiology laboratories and were supplemented by stock cultures of recent clinical isolates of some species to achieve target numbers. These included 411 aerobic and facultatively anaerobic bacteria representing 29 species, 61 anaerobic bacteria, and 10 yeast isolates, five of which were fluconazole resistant. (For  individual species, see Tables 2 and 4.) Antimicrobial agents. MSI-78 was provided by Magainin Pharmaceuticals, Inc., Plymouth Meeting, Pa., as a standardized powder with 100% potency (deionized water was used as the diluent). Standardized powders of ofloxacin, ceftazidime, cefuroxime, ciprofloxacin, and fluconazole were provided by their respective U.S. manufacturers, and ampicillin, cefazolin, gentamicin, oxacillin, penicillin G, piperacillin, cefoxitin, metronidazole, and amphotericin B were purchased from Sigma Chemicals, St. Louis, Mo.
Test methods.
Bacteria that grew aerobically were tested by broth microdilution, following the procedure outlined by the NCCLS (7) . Based on the results of the preliminary study and the recommendation of the supplier (3a), unsupplemented Mueller-Hinton broth was used for testing MSI-78, whereas cationadjusted Mueller-Hinton broth was used for all other antibiotics tested against aerobes. Test concentrations of MSI-78 were serial twofold dilutions ranging from 256 to 0.125 g/ml distributed in Dynatech microdilution trays. For the remaining antibiotics, only breakpoint concentrations were tested.
For 161 of these aerobic isolates (approximately five per species), bactericidal endpoints were also determined, following the method recommended by the NCCLS (8) .
Anaerobic bacteria were also tested by broth microdilution, which was performed in accordance with the procedure outlined by the NCCLS (9) . This utilized a broth version of Wilkins-Chalgren medium with 3% horse serum added when needed to support growth. Test concentrations for MSI-78 were the same as for testing aerobic bacteria. Ofloxacin and cefoxitin concentrations tested were twofold dilutions ranging from 32 to 0.06 g/ml. Clindamycin, metronidazole, penicillin G, and piperacillin were tested at breakpoint concentrations only.
Susceptibilities of yeasts were determined by the NCCLS broth macrodilution reference method (10), using RPMI 1640 broth. Test concentrations of MSI-78 were twofold dilutions ranging from 512 to 0.25 g/ml. Test concentrations of ofloxacin, amphotericin B, and fluconazole were 16 to 0.03 g/ml, 128 to 0.06 g/ml, and 256 to 0.25 g/ml, respectively. a 50% and 90%, MICs at which 50 and 90% of the isolates are inhibited, respectively. b Abbreviations (susceptibility breakpoints are in parentheses): OFLX, ofloxacin (Յ2.0 g/ml); AMP, ampicillin (Յ8.0 g/ml); CFU, cefuroxime (Յ8.0 g/ml); CFZ, cefazolin (Յ8.0 g/ml); CTAZ, ceftazidime (Յ8.0 g/ml); CIP, ciprofloxacin (Յ1.0 g/ml); GEN, gentamicin (Յ4.0 g/ml); PIP, piperacillin (Յ16 g/ml 
RESULTS AND DISCUSSION
The results of the preliminary study evaluating the effects of different media and incubation atmospheres on the MICs of MSI-78 when 10 strains of S. aureus are tested are summarized in Table 1 . Compared to the MICs observed with the standard method (cation-adjusted Mueller-Hinton broth incubated in ambient air), greatly increased MICs were observed with incubation in 5 to 7% CO 2 or in an anaerobic atmosphere and with the presence of agar or lysed horse blood in the medium. Using agarose to solidify the medium, however, significantly lowered the MICs, presumably due to its lower cation content. The use of unsupplemented Mueller-Hinton broth resulted in slightly lower MICs than did the use of the cation-adjusted medium. A larger difference was observed with other organisms (data not shown).
The modal MIC of MSI-78 for the 411 bacterial isolates that grew aerobically was 16 g/ml, with a range of Յ0.125 to Ͼ256 g/ml. The MIC distribution for MSI-78 is graphically displayed in Fig. 1 . For purposes of data analysis in this report, we considered any organism for which the MIC was Յ64 g/ml susceptible to MSI-78: that was based on the population statistics alone. Since the drug is being employed as a topical agent in a 1% formulation (10,000 g/g), concentrations well above 64 g/ml can be expected at the point of contact with surface bacteria.
The MICs of MSI-78 for each species are summarized in Table 2. MSI-78 was active against all but one species (E. faecalis). In this series, the MSI-78 MICs for 10 methicillin-resistant S. aureus strains were four-to eightfold higher than those for 15 methicillin-susceptible strains, but all were inhibited by Յ64 g of MSI-78/ml. E. faecalis was the only enterococcus tested and it consistently required more than 64 g of MSI-78/ml for inhibition. The percentages of isolates susceptible to Յ64 g of MSI-78/ml compared to 10 other antimicrobial agents are also shown in Table 2 . The percentage of all 411 isolates susceptible to concentrations of MSI-78 of Յ64 g/ml (91%) was comparable to rates of susceptibility to ciprofloxacin (92%) and ofloxacin (91%), and these three drugs were the most active against the population studied.
Tests for bactericidal activity showed MSI-78 to be bactericidal and equivalent to ofloxacin ( Table 3 ). The minimum bactericidal concentrations (MBCs) of MSI-78 were within one twofold dilution of the MICs for 93% of 161 organisms with on-scale endpoints, compared to 90% for ofloxacin. There was no cross-correlation for strains for which MBCs were Ն4 times the MIC for the two compounds.
The MICs of MSI-78 for anaerobes ranged from 0.25 to 128 g/ml (Table 4) . Of the 61 anaerobes tested, 97% were susceptible to MSI-78 at Յ64 g/ml. Only two strains (both Prevotella bivia) required more than 64 g/ml for inhibition. Of the six comparison drugs tested in parallel, only metronidazole had a greater percentage of susceptible isolates (100%); 57% were susceptible to ofloxacin.
For the 10 strains of C. albicans tested, the MSI-78 MICs ranged from 64 to Ͼ512 g/ml. At the 24-h reading, three (30%) were inhibited by 64 g of MSI-78/ml, but only two remained at this level at the 48-h reading. None were susceptible to ofloxacin (MICs of Ͼ16 g/ml), half were susceptible to fluconazole (Յ8.0 g/ml), and all were susceptible to amphotericin B (Յ1.0 g/ml). Of the two MSI-78-susceptible strains (at 48 h), one was fluconazole susceptible and one was fluconazole resistant.
Since MSI-78 acts directly on the anionic phospholipid of the bacterial cell membrane and not on membrane receptors (2), the development of resistance is theoretically less likely to occur. At least one study supports this (4) . In light of the current widespread increase in microbial resistance to most other antimicrobial agents, this characteristic plus its broad spectrum of antimicrobial activity makes MSI-78 an agent meriting further study. So far, however, such studies have been limited to topical applications. a Abbreviations (susceptibility breakpoints are in parentheses): OFLX, ofloxacin (Յ2.0 g/ml); CFOX, cefoxitin (Յ16 g/ml); CLIN, clindamycin (Յ2.0 g/ml); MET, metronidazole (Յ8.0 g/ml); PEN, penicillin G (Յ0.5 g/ml); PIP, piperacillin (Յ32 g/ml).
